Oxurion Announces Postponement of Signing for Strategic Transaction Due to Ongoing Discussions

31 Dec 2024 18:00 CET

LEUVEN, BELGIUM –31 December 2024 – 6:00PM, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, announces a short postponement of approximately four weeks for the signing of its contemplated strategic transaction. The delay is due to ongoing discussions between the parties, prompted by the better than expected financial results of the target.

The contemplated transaction, which represents a significant step in Oxurion's strategic realignment, remains a key priority for all parties involved. The Company confirms the shared willingness and commitment of all stakeholders to successfully finalize the agreement and to ensure the transaction's alignment with the updated financial context.

With this adjustment to the timeline, Oxurion reiterates its dedication to completing the transaction and achieving its strategic objectives. Further updates will be provided as key milestones are reached.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in the development of next-generation standard ophthalmic therapies for the treatment of retinal diseases. Oxurion is headquartered in Leuven. Further information is available at www.oxurion.com

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

89328_BE0974487192.pdf